Related Experiment Videos
Bivalent ligand type beta-adrenolytics related to practolol
Drugs Under Experimental and Clinical Research
|January 1, 1988
Summary
Researchers synthesized and evaluated novel beta-adrenolytic drugs. The most effective compound was N,N'-bis[3-[2-hydroxy-3-[1-methylethyl)amino]propoxy]phenyl] ethanediamide, showing promising pharmacological activity.
Area of Science:
- Medicinal Chemistry
- Pharmacology
Background:
- Beta-adrenolytics are crucial for managing cardiovascular conditions.
- Practolol is a known beta-adrenolytic agent.
Purpose of the Study:
- To synthesize and pharmacologically evaluate novel symmetrical bivalent ligand type beta-adrenolytics.
- To identify compounds with improved therapeutic potential related to practolol.
Main Methods:
- Synthesis of symmetrical bivalent ligand beta-adrenolytics.
- Pharmacological evaluation of synthesized compounds.
Main Results:
- Several novel beta-adrenolytic compounds were successfully synthesized.
- N,N -bis[3-[2-hydroxy-3-[1-methylethyl)amino]propoxy]phenyl] ethanediamide demonstrated the most significant pharmacological activity.
Conclusions:
- The synthesized bivalent ligands show potential as beta-adrenolytic agents.
- N,N -bis[3-[2-hydroxy-3-[1-methylethyl)amino]propoxy]phenyl] ethanediamide is a lead compound for further development.